Philadelphia College of Osteopathic Medicine

DigitalCommons@PCOM
PCOM Physician Assistant Studies Student
Scholarship

Student Dissertations, Theses and Papers

2022

Is phentermine/topiramate ER with lifestyle modifications
effective in achieving weight loss in obese patients with
comorbidities?
Elizabeth A. Stubbs
Philadelphia College of Osteopathic Medicine

Follow this and additional works at: https://digitalcommons.pcom.edu/pa_systematic_reviews
Part of the Medicine and Health Sciences Commons

Recommended Citation
Stubbs, Elizabeth A., "Is phentermine/topiramate ER with lifestyle modifications effective in achieving
weight loss in obese patients with comorbidities?" (2022). PCOM Physician Assistant Studies Student
Scholarship. 615.
https://digitalcommons.pcom.edu/pa_systematic_reviews/615

This Selective Evidence-Based Medicine Review is brought to you for free and open access by the Student
Dissertations, Theses and Papers at DigitalCommons@PCOM. It has been accepted for inclusion in PCOM
Physician Assistant Studies Student Scholarship by an authorized administrator of DigitalCommons@PCOM. For
more information, please contact jaclynwe@pcom.edu.

Is phentermine/topiramate ER with lifestyle modifications effective
in achieving weight loss in obese patients with comorbidities?

Elizabeth A. Stubbs, PA-S
A SELECTIVE EVIDENCE BASED MEDICINE REVIEW
In Partial Fulfillment of the Requirements For
The Degree of Master of Science
In
Health Sciences – Physician Assistant

Department of Physician Assistant Studies
Philadelphia College of Osteopathic Medicine
Philadelphia, Pennsylvania

December 17, 2021

ABSTRACT
Objective: The objective of this selective EBM review is to determine whether or not “Is
phentermine/topiramate ER with lifestyle modifications effective in achieving weight loss in
obese patients with comorbidities?”
Study Design: A systematic review of three placebo-controlled randomized controlled trials
(RCTs) published in English in 2012 or after.
Data Sources: All three studies were found by searching PubMed and were published in peerreviewed journals. The articles were selected based on ability to answer the proposed question.
Outcome Measured: Percent weight loss was the outcome measured in all three studies. This
was measured based on mean percent weight loss from baseline at various weekly intervals.
Results: Aronne, et al, conducted a double-blind RCT that showed phentermine/topiramate
(PHEN/TPM ER) 15/92 mg produced greater percent weight loss at every 4 weeks than the
placebo group (p < 0.05) with LS mean percent weight loss of -11.63 compared to placebo at 2.28 for mITT analysis. 8 The ITT-LOCF analysis showed LS mean percent weight loss of -1.71
for the placebo and -9.21 for PHEN/TPM ER (p < 0.05). 8 The Winslow, et al double-blind RCT
found a LS mean percent weight loss from baseline of -10.3% (standard error 1.17) for
PHEN/TPM ER and -4.2% (standard error 1.15) for placebo (p = 0.0006). 9 Garvey, et al’s
double-blind RCT showed that PHEN/TPM ER produced a LS mean percent weight loss of
12.1% and the placebo group only achieved 2.5% (ITT-MI; p = 0.0001). 10
Conclusion: The three studies in this review found PHEN/TPM ER to produce greater weight
loss that was statistically significant when compared to placebo. This demonstrates the utility of
PHEN/TPM ER in helping patients achieve weight loss and subsequently reduce the prevalence
or risk of obesity-related comorbidities. Further research should be conducted to assess the role
lifestyle modifications play in the success of PHEN/TPM ER and to determine its effectiveness
in adolescents.
Key Words: phentermine, topiramate, extended release, obesity
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INTRODUCTION
Obesity is diagnosed based on having a BMI (body mass index) of 30.0 or higher. This
can be further subdivided into Class I Obesity – BMI of 30.0-34.9, Class II Obesity – BMI of
35.0-39.9, and Class III Obesity – BMI ≥ 40.0.1 Both genetics and environmental factors
contribute to the development of obesity.1 Obesity increases an individual’s risk for developing
other comorbidities like heart disease, diabetes, hyperlipidemia, OSA, etc. The National Health
and Nutrition Survey’s (NHANES) data has shown a steady rise in obesity within the US
regardless of age, gender, race, or ethnicity since the 1970s.2 About 30% of the world, more than
2.1 billion people, in 2014 were overweight or obese.3 The prevalence of obese adults in the US
was 42.4% in 2017-2018.4 The economic impact of obesity globally in 2014 was estimated at
$2.0 trillion.3 Data from 2014 determined that annual medical spending nationwide for obesity
was $149.4 billion.5 11 million office visits for obesity among adults 20 years and older in the
US were made in 2012.6
It is known that obesity can be caused by a multitude of things including lifestyle,
genetics, and other medical conditions. There are many avenues to achieve weight loss, but there
is no known treatment that is 100% effective in all people. No one size fits all regimen exists and
often achieving and maintaining weight loss takes many months and even years. The mainstay
treatment regimen for obesity is diet modification, including being in a calorie deficit, following
a low fat/low carb diet, etc., and exercise of an average of 30 minutes a day, 5 days a week.
Other pharmacological treatment options include liraglutide, semaglutide, and orlistat to name a
few. Usually as a last resort surgery can be considered such as gastric bypass (Roux-en-Y
procedure), gastric banding, or sleeve gastrectomy.
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Phentermine alone can be used for weight loss, but only for a short term. It is a
sympathomimetic amine anorectic and therefore causes the release of norepinephrine and
epinephrine.7 It essentially helps decrease appetite. Topiramate is used as an anticonvulsant and
prophylaxis for migraines, but also curbs appetite and increases feelings of fullness.7 The
combination of these two medications along with lifestyle modifications can enable and sustain
weight loss. This combination medication, phentermine/topiramate ER (PHEN/TPM ER), goes
by the brand name Qsymia and is a once daily dosing that can be taken indefinitely. It is
available in 3.75/23mg, 7.5/46mg, 11.25/69mg, 15/92mg capsules.7 This combination
medication has been shown to result in increased weight loss compared to either medication as
monotherapy. This review discusses three randomized controlled trials that analyze the
effectiveness of PHEN/TPM ER for weight loss in obese adults (≥ 18 years old) who have
various comorbidities including metabolic syndrome, prediabetes, and obstructive sleep apnea.
OBJECTIVE
The objective of this selective EBM review is to determine whether or not “Is
phentermine/topiramate ER with lifestyle modifications effective in achieving weight loss in
obese patients with comorbidities?”
METHODS
The three articles discussed in this paper were chosen based on their ability to answer the
proposed clinical question as stated in the objective. The studies were all double blind and were
selected based on the criteria of being randomized control trials published in or after 2010, in
English, and in peer-reviewed journals. PubMed was searched to find the selected articles using
the key words “phentermine”, “topiramate”, “extended release”, and “obesity”. All the articles
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utilized the same basic population of obese adults, determined to be at least 18 years old with a
of BMI 27-45 kg/m2, with various comorbidities. The three chosen articles also all used the
intervention of PHEN/TPM ER 15/92 mg with lifestyle modifications, the comparison of
placebo with lifestyle modifications, and measured the patient-oriented outcome (POEM) of
percent weight loss from baseline. The lifestyle intervention utilized in all three studies was
based on the LEARN program (Lifestyle, Exercise, Attitude, Relationships, Nutrition). Studies
that used only PHEN/TPM CR or did not include lifestyle modifications along with
pharmacological treatment were excluded from consideration. The statistics reported in the
selected articles were LS means and p values. Reference Table 1 below for demographics and
characteristics of the three selected studies.
Table 1. Demographics & Characteristics of Included Studies
Study

Type
RCT

#
Patients
756

Age
(yrs)
18-70

Inclusion
Criteria
18-70 yrs old,
BMI ≥ 30 and ≤
45 kg/m2

Aronne, et
al8 (2013)

Winslow,
et al9
(2012)

RCT

45

30-65

30-65 yrs old
with BMI 3040kg/m2, severe
OSA syndrome,
AHI ≥ 15 at
baseline and
can’t/won’t
comply with
PAP treatment
(compliance: > 4
hrs/night, 70% of
the time)

Garvey, et
al10 (2014)

RCT

475

18-70

18-70 yrs old,
BMI 27-45

Exclusion Criteria

W/D

Interventions

Within the last 3
months, use of
phentermine or
topiramate, weight
gain or loss of > 5kg,
very low calorie diet,
use of
pharmacotherapy for
weight loss, or
participation in
weight loss program
Sleep disorder other
than OSA, periodic
limb movement
arousal index > 10,
poorly/uncontrolled
BP (sys > 160 or dia
> 100), or
history/diagnosed
with unstable angina,
heart failure, cardiac
valvulopathy, MI,
life-threatening
arrhythmia, or
significant
abnormality on EKG
Subjects from the
original study

261

PHEN/TPM ER
15/92 mg +
lifestyle
counseling vs.
placebo +
lifestyle
counseling; for
28 weeks

5

PHEN/TPM ER
15/92 mg +
lifestyle
counseling vs.
placebo +
lifestyle
counseling; for
28 weeks

77

PHEN/TPM ER
15/92 mg +
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kg/m2,
prediabetes
and/or metabolic
syndrome

diagnosed with Type
II DM were excluded
from the extension
study

lifestyle
counseling vs.
placebo +
lifestyle
counseling; for
108 weeks

OUTCOMES MEASURED
Weight loss is the patient-oriented outcome assessed in this evidence based medicine
review. In the three selected studies this was measured based on mean percent weight loss from
baseline at various weekly intervals. The study conducted by Aronne, et al8 (2013) and Winslow,
et al9 (2012) conducted their last weigh-in of participants at the end of 28 weeks, and the Garvey,
et al10 (2014) study which was an extension of a previous study conducted their last weigh-in at
108 weeks.
RESULTS
A double blind RCT was conducted by Aronne, et al to determine the effectiveness of
PHEN/TPM ER 15/92 mg for weight loss in obese adults determined by a BMI between 30 and
45 kg/m2. 8 The study ran from December 2007 to September 2008. Inclusion and exclusion
criteria for participants are described in detail in Table 1. Subjects were randomized to treatment
groups and blinding was achieved by masking group assignment to both staff and participants. In
addition, the drug capsules were masked to all look identical. 8 109 participants were randomized
to the placebo group and 108 into the PHEN/TPM ER 15/92 mg group. 8 Participants in the
treatment group were started at a dose of 3.75/23 mg daily and the dose was increased weekly
over a 4-week period to reach the desired treatment dose. 8 The placebo group underwent the
same “titration”. All participants also received lifestyle intervention based on the LEARN
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manual and discussed their progress at brief monthly visits. 8 Participants were weighed every 4
weeks until the study was completed at the end of 28 weeks.
Out of the total 756 enrolled participants, 261 (34.5%) discontinued the study and the
dropout percentages were comparable across treatment groups.8 Reasons for discontinuation
included loss to follow-up, withdrawal of consent, or adverse events. 8 No serious adverse events
were found to be the result of PHEN/TPM ER. 8 Last observation carried forward (LOCF) was
used to fill in these participants’ missing data for intention to treat (ITT) analysis, and a separate
modified ITT analysis was also conducted. 8 In both the mITT and ITT-LOCF analyses,
PHEN/TPM ER 15/92 mg was found to result in a statistically significant greater percent weight
loss at every 4 weeks than placebo (p < 0.05). 8 At 28 weeks the LS mean percent weight loss
(mITT) for the placebo group was -2.28 and for PHEN/TPM ER 15/92 mg was -11.63. 8 The
ITT-LOCF analysis at 28 weeks respectively showed LS mean percent weight loss of -1.71 for
the placebo and -9.21 for PHEN/TPM ER 15/92 mg (p < 0.05). 8
Table 2. LS Mean Percent Weight Loss at Week 28
mITT
ITT-LOCF
Placebo
-2.28
-1.71
PHEN/TPM ER -11.63
-9.21
15/92mg
P-value
< 0.05
< 0.05
Winslow, et al also conducted a double blind RCT to investigate the effectiveness of
PHEN/TPM ER 15/92 mg for weight loss in obese adults, but their participants also had
moderate to severe obstructive sleep apnea (OSA).9 This study ran from August 2008 to
September 2009 and encompassed 45 participants with BMIs between 30-40 kg/m2. 9 Table 1
outlines the specific inclusion and exclusion criteria for participants that was used. All
participants received lifestyle modification counseling with the LEARN program. 9 Subjects
were randomized to either PHEN/TPM ER 15/92 mg or placebo group with 22 and 23
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participants in each respectively. 9 Just like the study conducted by Aronne, et al, there was a 4week titration period of the medication where the dose was increased weekly by 3.75mg of
phentermine and 23mg of topiramate until the desired dose. 9 Once the desired dose was
achieved subjects were followed for an additional 24 weeks. Follow up visits with participants
occurred every 4 weeks. 9
Of the 45 participants who were randomized into groups, only 5 did not complete the
study due to adverse events or withdraw of consent. 9 Those who did not complete the study
accounted for 11% of the enrolled participants. There were 2 participants who discontinued the
study from the placebo group and 3 from the PHEN/TPM ER group. 9 Analysis using LOCF for
mean percent weight loss in the two groups was done using the data collected at weeks 8 and 28.
LS mean percent weight loss at week 8 was -5.6% (standard error 0.59) for the PHEN/TPM ER
group and -2.3% (standard error 0.59) for placebo group (p = 0.0003). 9 By the completion of the
study at week 28, LS mean percent weight loss from baseline was -10.3% (standard error 1.17)
for PHEN/TPM ER and -4.2% (standard error 1.15) for placebo (p = 0.0006). 9 A placeboadjusted LS mean percent weight loss was also conducted and found to be -3.3 at week 8 (95%
CI: -5.0, -1.6; p = 0.0003) and -6.1 at week 28 (LOCF; 95% CI: -9.4, -2.7; p = 0.0006). 9
Table 3. LS Mean Percent Weight Loss at Weeks 8 and 28
Placebo
PHEN/TPM ER 15/92mg
Week 8
-2.3% (standard
-5.6% (0.59)
error 0.59)
Week 28
-4.2% (1.15)
-10.3% (1.17)

P-value
0.0003
0.0006

Like the previously discussed studies, Garvey, et al also conducted a double blind,
placebo-controlled RCT investigating the effects of PHEN/TPM ER 15/92 mg in obese adults
(BMI 27-45 kg/m2). 10 This study, called SEQUEL, lasted 52 weeks and was an extension of the
phase 3 CONQUER study that assessed weight loss using PHEN/TPM ER in obese adults with 2
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or more obesity-related comorbidities over 56 weeks. 10 SEQUEL’s specific participant
population also had prediabetes, as defined by the American Diabetes Association, and/or
metabolic syndrome. 10 The entirety of this study, including both CONQUER and SEQUEL, ran
from December 2008 to June 2010, a total of 108 weeks. 10 475 participants were enrolled into
SEQUEL based on criteria detailed in Table 1, and they remained in their same randomly
assigned treatment groups from the CONQUER study. 10 451 participants were diagnosed with
metabolic syndrome, 316 with prediabetes, and 292 had both conditions. 10 The placebo group
had 159 participants and PHEN/TPM ER group had 201.10 Baseline demographics and clinical
features were comparable across treatment groups. 10 All participants received lifestyle
modification counseling using the LEARN program just like the previously discussed studies.
Participants had follow-up visits every 4 weeks for a total of 108 weeks where their weight was
measured and lifestyle modifications were discussed. 10
Only 398 participants, 84% of original participants, completed the study and had data at
week 108. 10 Withdraw from the study due to treatment emergent adverse events occurred in
3.1% of the placebo and 5.5% of the PHEN/TPM ER group. 10 Both multiple imputation (MI),
using a two-step imputation process, and LOCF were utilized separately to fill in missing data
for analysis purposes. 10 Analysis was conducted using ANCOVA on the ITT population for the
entirety of the 108 weeks. 10 The difference in weight loss between the two groups was found to
be statistically significant, with PHEN/TPM ER producing a greater deficit at every time point
assessed in analysis. 10 The PHEN/TPM ER group was found to have a LS mean percent weight
loss of 12.1% and the placebo group only had 2.5% (ITT-MI; p = 0.0001). 10 Analysis using ITTLOCF showed similar results to ITT-MI. 10
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Table 4. LS Mean Percent Weight Loss at Week 108
Placebo
PHEN/TPM ER 15/92mg
Week 108
2.5%
12.1%

P-value
0.0001

DISCUSSION
PHEN/TPM is a schedule IV medication due to the fact that phentermine is similar to
amphetamines which are often abused for their stimulant properties.11 A Risk Evaluation and
Mitigation Strategy (REMS) was enacted by the FDA for PHEN/TPM to ensure safe use of the
medication, and therefore has limited availability as only certified pharmacies can distribute it.11
Currently this medication is only available for use in adults with a BMI ≥ 27 kg/m2 and at least
one weight-related comorbidity.11 A similar titration strategy to the one utilized in the three
studies discussed for PHEN/TPM is recommended for initiating therapy. A starting dose of
3.75/23mg is taken for 14 days and then titrated up to the desired dose, not to exceed 15/92mg.11
The medication is best tolerated if taken in the morning as opposed to bedtime to avoid
insomnia.11 Dose restrictions exist for patients with renal and hepatic impairments. If CrCl ≥ 30
mL/min, a daily dosage of PHEN/TPM 7.5/46 mg should not be exceeded.11 Those with severe
hepatic impairment should not use this medication.11
Abrupt discontinuation of PHEN/TPM can result in seizures and thus it needs to be
gradually tapered.11 Besides insomnia, other common side effects include dizziness, constipation,
dry mouth, paresthesia, and altered taste.11 Absolute contraindications to taking this medication
include pregnancy (due to risk of fetal harm and birth defects), use of an MAOI within the last
14 days, glaucoma, hyperthyroidism, or known hypersensitivity to sympathomimetic amines.11
Prescribers also need to monitor patients for changes in behavior such as suicidal thoughts and
depression as suicidality can occur while taking this medication.11
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In all three of the discussed studies, PHEN/TPM ER was found to cause a significant
percent weight loss when compared to placebo. All three studies demonstrated results that were
statistically significant with p-values < 0.05 and large effect sizes. Weight loss was achieved in
all three studies even though they had participant populations with varying comorbidities. These
findings indicate a wide-ranging effectiveness of PHEN/TPM and support its continued use and
prevalence in obese participants across the board. Winslow, et al9 and Garvey, et al10 conducted a
couple different analyses to account for participants that dropped out of the study and all were
found to be statistically significant demonstrating the effectiveness of PHEN/TPM ER. It is
important to note that all the studies enacted the LEARN lifestyle modification program for all
participants in order to control for any differences and standardize the educational information
participants received on this topic. PHEN/TPM ER is intended to be taken in combination with
lifestyle modifications and therefore by implementing the LEARN program, the studies intended
the results to reflect this.
These studies were not without their limitations. Even though the LEARN program was
used across all three studies and all treatment groups, it is not clear in any of the studies the
extent to which participants incorporated these lifestyle modifications into their daily routines.
Compliance with the LEARN program should have been better monitored and evaluated as this
could have impacted results. A major limitation throughout all three studies was that worst case
analysis for participants who did not complete the study was not performed. Aronne, et al8 had
the largest dropout rate with 34.5% of their original participants not completing the study.
Sample size was also an issue in the Winslow, et al9 study with only 45 enrolled participants.
Both the Aronne, et al8 and Winslow, et al9 studies lasted only 28 weeks, which was an
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acceptable amount of time, but could have been extended to demonstrate the long-term
effectiveness of PHEN/TPM ER since it is designed for chronic weight management.
Since the Garvey, et al10 study was an extension study, it came with a unique set of
limitations. For example, only treatment centers that had high-enrollment and participant
retention were utilized to recruit for the SEQUEL study. 10 These treatment centers achieved
slightly higher weight loss in the CONQUER study compared to other centers. 10 These
participant selection factors introduced an element of bias that likely influenced the resulting
data. Also of note, a higher percentage of participants in the PHEN/TPM ER treatment arm
elected to participate in the SEQUEL study and therefore the original 2:1:2 randomization ratio
was not maintained from the original CONQUER study.10 These reasons could all contribute to
some bias in the overall study and subsequent results that were found.
CONCLUSION
The findings of these three studies all clearly answer the question that indeed
PHEN/TPM ER plus lifestyle modifications is effective in achieving weight loss in obese adults.
Despite participants all having various obesity-related comorbidities, Aronne, et al8, Winslow, et
al9, and Garvey, et al10 all found statistically significant weight loss with PHEN/TPM ER
compared to placebo with p-values < 0.05. For future research on this topic it would be
beneficial to assess the role lifestyle modifications play in the success of PHEN/TPM ER in
achieving weight loss. Future studies can control the lifestyle modifications participants utilize
by having scheduled workouts and meal preparation services in addition to educational
information about healthy diet and exercise. At the very least the lifestyle modifications should
be monitored to track subjects’ participation and see if this was consistent across treatment
groups as this could greatly impact results.
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It would also be informative to pursue additional studies investigating the effectiveness of
PHEN/TPM in other comorbidities where obesity is a common symptom and weight loss is
notoriously challenging, such as hypothyroidism and polycystic ovarian syndrome. If
PHEN/TPM is proven effective in these populations, it could have profound effects on not only
their disease course, but also their overall physical and mental health state. Although the study
by Garvey, et al10 ran for 108 days which was significantly longer than the other two studies,
future studies of even longer duration, such as a longitudinal study, would be beneficial to see if
PHEN/TPM ER can help obese adults maintain and/or continue achieving weight loss over the
years. As the popularity of weight loss medications continues to rise, future studies should look
into comparing these medications to each other to see not only which medication achieves
weight loss, but which sustains it over time.
The majority of weight loss medications are only approved for use in adults. Currently
however there are clinical trials in progress assessing the use of PHEN/TPM ER in adolescents.
At the University of Minnesota there are two ongoing trials with one investigating PHEN/TPM
for achieving weight loss in severely obese children ages 12-2012, and the other looking at
PHEN/TPM’s use in obese adolescents (ages 12-18) with Type 2 diabetes.13 This research would
greatly impact the ongoing prevalence of childhood obesity by hopefully providing evidence for
the use of these weight loss medications in the adolescent patient population.
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